A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease.
paper
Cited
Public
- Authors
- Huang, Kuan-Lin; Marcora, Edoardo; Pimenova, Anna A; Di Narzo, Antonio F; Kapoor, Manav; Jin, Sheng Chih; Harari, Oscar; Bertelsen, Sarah; Fairfax, Benjamin P; Czajkowski, Jake; Chouraki, Vincent; Grenier-Boley, Benjamin; Bellenguez, Céline; Deming, Yuetiva; McKenzie, Andrew; Raj, Towfique; Renton, Alan E; Budde, John; Smith, Albert; Fitzpatrick, Annette; Bis, Joshua C; DeStefano, Anita; Adams, Hieab H H; Ikram, M Arfan; van der Lee, Sven; Del-Aguila, Jorge L; Fernandez, Maria Victoria; Ibañez, Laura; International Genomics of Alzheimer's Project; Alzheimer's Disease Neuroimaging Initiative; Sims, Rebecca; Escott-Price, Valentina; Mayeux, Richard; Haines, Jonathan L; Farrer, Lindsay A; Pericak-Vance, Margaret A; Lambert, Jean Charles; van Duijn, Cornelia; Launer, Lenore; Seshadri, Sudha; Williams, Julie; Amouyel, Philippe; Schellenberg, Gerard D; Zhang, Bin; Borecki, Ingrid; Kauwe, John S K; Cruchaga, Carlos; Hao, Ke; Goate, Alison M
- Year
- 2017
- Journal
- Nature neuroscience
- PMID
- 28628103
- DOI
- 10.1038/nn.4587
- PMCID
- PMC5759334
A genome-wide survival analysis of 14,406 Alzheimer's disease (AD) cases and 25,849 controls identified eight previously reported AD risk loci and 14 novel loci associated with age at onset. Linkage disequilibrium score regression of 220 cell types implicated the regulation of myeloid gene expression in AD risk. The minor allele of rs1057233 (G), within the previously reported CELF1 AD risk locus, showed association with delayed AD onset and lower expression of SPI1 in monocytes and macrophages. SPI1 encodes PU.1, a transcription factor critical for myeloid cell development and function. AD heritability was enriched within the PU.1 cistrome, implicating a myeloid PU.1 target gene network in AD. Finally, experimentally altered PU.1 levels affected the expression of mouse orthologs of many AD risk genes and the phagocytic activity of mouse microglial cells. Our results suggest that lower SPI1 expression reduces AD risk by regulating myeloid gene expression and cell function.
Genetic and eQTL fine-mapping of AD(a) The AD-survival association landscape at the CELF1/SPI1 locus resembles that of SPI1 eQTL association in monocytes and macrophages. (b) The AD-survival association landscape resembles that of MS4A4A/MS4A6A eQTL association in monocytes and macrophages.
SPI1 (PU.1) expression and ChIP-Seq analysis(a) Rs1057233G is associated with reduced SPI1 expression in a dosage-dependent manner. (b) The mouse homolog of SPI1, Sfpi1 or Spi1, is selectively expressed in microglia and macrophages in mouse brains based on the brain RNA-Seq database29–31. OPCs contain 5% microglial contamination. (c) SPI1 (PU.1) binds to the promoter and regulatory regions of CD33, MS4A4A, MS4A6A, TREM2, and TREML2 in human CD14+ monocytes based on ChIP-Seq data35.
PU.1 modulates the phagocytic activity of BV2 microglial cells(a) Phagocytosis of zymosan labeled with red pHrodo fluorescent dye in BV2 cells with transient overexpression and knock-down of PU.1 was measured by flow cytometry. Cytochalasin D treatment was used as a negative control. Mean phagocytic index ± SD is shown: pcDNA 0.7373 ± 0.1772, pcDNA + 1 μM Cyt 0.0236 ± 0.0242, FLAG-PU.1 1.2630 ± 0.2503, shSCR 1.014 ± 0.3656, shA 0.4854 ± 0.1209, shB 0.2579 ± 0.06967, shD 0.2002 ± 0.05168. F(6,13) = 14.82, pcDNA vs pcDNA + 1 μM Cyt P=0.0078, pcDNA vs FLAG-PU.1 P=0.0295, shSCR vs shA P=0.0283, shSCR vs shB P=0.0020, shSCR vs shD P=0.0010, n = 3. (b) BV2 cells were transiently transfected with pcDNA3 (pcDNA) or pcDNA3-FLAG-PU.1 (FLAG-PU.1) and pCMV-GFP as described for phagocytosis assay. Note a shift in mobility of the band for exogenous FLAG-PU.1 in overexpression condition compared to endogenous PU.1 in control. (c) BV2 cells were transiently transfected with shRNA targeting PU.1 (shA, shB and shD) or non-targeting control (shSCR) in pGFP-V-RS vector. GFP+ cells were sorted with flow cytometer and analyzed for levels of PU.1 in western blotting in two independent experiments (b, c). (d) Quantification of PU.1 levels in c normalized to β-Actin as a loading control. Values are presented as mean ± SD: shSCR 100 ± 2.10, shA 50.34 ± 9.52, shB 16.03 ± 14.72, shD 12.13 ± 10.03. F(3,6) = 70.55, shSCR vs shA P=0.0014, shSCR vs shB P < 0.0001, shSCR vs shD P < 0.0001, n = 2. * P < 0.05, ** P < 0.01, *** P < 0.001, one-way ANOVA with Sidak’s post hoc multiple comparisons test between selected groups.
Genes regulated with differential expression of Spi1 in BV2 microglial cellsqPCR analysis in transiently transfected and sorted GFP+ BV2 cells with overexpression (FLAG-PU.1) and knock-down (shB) of Spi1. Changes in expression levels are grouped for genes with altered levels after overexpression and knock-down of Spi1 in (a) and genes with variable expression in BV2 cells either with overexpression (b) or knock-down (c) of Spi1. Values are presented as mean ± SD, n = 4 samples collected independently. * P < 0.05, ** P < 0.01, *** P < 0.001, one-way ANOVA with Dunnett’s post hoc multiple comparisons test between experimental and control groups, detailed statistical analysis is reported in Supplementary Table 11.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A common 19 bp APOE enhancer deletion is protective against Alzheimer's disease in African Americans. | Brutman JN et al. | — | 2026 | → |
| Epigenomic subtypes of late-onset Alzheimer's disease reveal distinct microglial signatures. | Laroche VT et al. | — | 2026 | → |
| Genetic Architecture of Cognitive Resilience in Alzheimer's Disease: Mechanisms, Pathways, and Therapeutic Implications. | Burdman G et al. | — | 2026 | → |
| Macrophage polarization in tumors: The impact of efferocytosis. | Zhang Y et al. | — | 2026 | → |
| MerTK-triggered TGFβ1 autocrine signal regulates microglial response to neurodegeneration. | Huang Y et al. | — | 2026 | → |
| Microglial phagocytosis in epilepsy: Mechanisms and impact. | Barath AS et al. | — | 2026 | → |
| Morroniside Modulates Microglia Polarization via the CX3CL1/CX3CR1/PU.1 Axis in ApoE4 Transgenic Mice. | Chang YY et al. | — | 2026 | → |
| Peripheral blood transcriptome signatures indicate environmental influences in monozygotic twins discordant for Alzheimer's disease. | Roh JH et al. | — | 2026 | → |
| Predicting disease-specific histone modifications and functional effects of non-coding variants by leveraging DNA language models. | Wang X et al. | — | 2026 | → |
| PU.1: the conductor of Alzheimer's symphony. | Sun C et al. | — | 2026 | → |
| Spil-mediated sEH overexpression contributes to the senescence of alveolar epithelial cells during pulmonary fibrosis in mice. | Zhang CY et al. | — | 2026 | → |
| The brain neurovascular epigenome and its association with dementia. | Ziegler KC et al. | — | 2026 | → |
| ZMAT1 Promotes Osteoclastogenesis Through TRIM46 Mediated YAP1 Degradation and Inhibits Osteoblastogenesis. | Chang X et al. | — | 2026 | → |
| Alzheimer's Disease Risk Variants Interact with Amyloid-Beta to Modulate Monocyte Function. | Chatila ZK et al. | — | 2025 | → |
| A neurodegenerative cellular stress response linked to dark microglia and toxic lipid secretion. | Flury A et al. | — | 2025 | → |
| Brain and blood transcriptome-wide association studies identify five novel genes associated with Alzheimer's disease. | Mews MA et al. | — | 2025 | → |
| Central Nervous System Macrophages in Health and Disease. | Van Hove H et al. | — | 2025 | → |
| Combating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition: Beyond <i>APOE</i>. | Ramanan VK et al. | — | 2025 | → |
| Cytokine-induced reprogramming of human macrophages toward Alzheimer's disease-relevant molecular and cellular phenotypes in vitro. | Podleśny-Drabiniok A et al. | — | 2025 | → |
| Design, current states, and challenges of nanomaterials in anti-neuroinflammation: A perspective on Alzheimer's disease. | Hong X et al. | — | 2025 | → |
| Generation of an Inducible Destabilized-Domain Cre Mouse Line to Target Disease Associated Microglia. | Henningfield CM et al. | — | 2025 | → |
| Genetic risk for neurodegenerative conditions is linked to disease-specific microglial pathways. | Askarova A et al. | — | 2025 | → |
| Human iPSC-Derived Microglia Integrate Into Cerebral Organoids and Assume an In Vivo-Like Phenotype. | Wogram E et al. | — | 2025 | → |
| Integrated analysis of chromatin and transcriptomic profiling of the striatum after cerebral hypoperfusion in mice. | Le S et al. | — | 2025 | → |
| Long-read RNA sequencing atlas of human microglia isoforms elucidates disease-associated genetic regulation of splicing. | Humphrey J et al. | — | 2025 | → |
| Lymphoid gene expression supports neuroprotective microglia function. | Ayata P et al. | — | 2025 | → |
| Multi-ancestry meta-analysis identifies genetic modifiers of age-at-onset of Alzheimer's disease at known and novel loci. | Blue EE et al. | — | 2025 | → |
| Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuum. | Ali M et al. | — | 2025 | → |
| Multi Layered Omics Approaches Reveal Glia Specific Alterations in Alzheimer's Disease: A Systematic Review and Future Prospects. | İş Ö et al. | — | 2025 | → |
| Muscle-driven spinal cord histological and transcriptomic alterations in a myotonic dystrophy mouse model: insights into neuropathy. | Shi G et al. | — | 2025 | → |
| Novel early-onset Alzheimer-associated genes influence risk through dysregulation of glutamate, immune activation, and intracellular signaling pathways. | Bradley J et al. | — | 2025 | → |
| Pro-resolving lipid mediator reduces amyloid-β42-induced gene expression in human monocyte-derived microglia. | Wang Y et al. | — | 2025 | → |
| Protective Genes Against Alzheimer's Disease: Case Review and Therapeutic Implications. | Hossain N et al. | — | 2025 | → |
| Pu.1/Spi1 dosage controls the turnover and maintenance of microglia in zebrafish and mammals. | Wu Y et al. | — | 2025 | → |
| Ramp Sequence May Explain Synonymous Variant Association with Alzheimer's Disease in the Paired Immunoglobulin-like Type 2 Receptor Alpha (PILRA). | Miller JB et al. | — | 2025 | → |
| Targeting <i>SPI1</i> to mitigate amyloid-β pathology in Alzheimer's disease. | Shao J et al. | — | 2025 | → |
| Transethnic analysis identifies SORL1 variants and haplotypes protective against Alzheimer's disease. | Zhou X et al. | — | 2025 | → |
| Unraveling the complex role of microglia in Alzheimer's disease: amyloid β metabolism and plaque formation. | Takatori S et al. | — | 2025 | → |
| Visualising the Knowledge Structure of Microglia in Alzheimer's Disease: A CiteSpace Analysis. | Wang Q et al. | — | 2025 | → |
| A systems biology-based identification and in vivo functional screening of Alzheimer's disease risk genes reveal modulators of memory function. | Hudgins AD et al. | — | 2024 | → |
| BHLHE40/41 regulate microglia and peripheral macrophage responses associated with Alzheimer's disease and other disorders of lipid-rich tissues. | Podleśny-Drabiniok A et al. | — | 2024 | → |
| Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development. | Ahmed H et al. | — | 2024 | → |
| Circulating blood circular RNA in Parkinson's Disease; from involvement in pathology to diagnostic tools in at-risk individuals. | Beric A et al. | — | 2024 | → |
| Coupling of Alzheimer's Disease Genetic Risk Factors with Viral Susceptibility and Inflammation. | Cao C et al. | — | 2024 | → |
| Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics. | Rexach JE et al. | — | 2024 | → |
| Distinct transcriptomic responses to Aβ plaques, neurofibrillary tangles, and APOE in Alzheimer's disease. | Das S et al. | — | 2024 | → |
| Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis. | Kim B et al. | — | 2024 | → |
| Epigenetic control of microglial immune responses. | Scholz R et al. | — | 2024 | → |
| Identification of female-enriched and disease-associated microglia (FDAMic) contributes to sexual dimorphism in late-onset Alzheimer's disease. | Wu D et al. | — | 2024 | → |
| Interpretation of Neurodegenerative GWAS Risk Alleles in Microglia and their Interplay with Other Cell Types. | Holtman IR et al. | — | 2024 | → |
| Lipid-nanoparticle-induced vacuolization in microglia. | Kerschbaum HH et al. | — | 2024 | → |
| Microglia in Health and Diseases: Integrative Hubs of the Central Nervous System (CNS). | Sierra A et al. | — | 2024 | → |
| Microglia Signatures: A Cause or Consequence of Microglia-Related Brain Disorders? | Mirarchi A et al. | — | 2024 | → |
| Nanoparticle-Mediated Delivery of Anti-PU.1 siRNA via Localized Intracisternal Administration Reduces Neuroinflammation. | Ralvenius WT et al. | — | 2024 | → |
| Prioritizing susceptibility genes for the prognosis of male-pattern baldness with transcriptome-wide association study. | Choi E et al. | — | 2024 | → |
| Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease. | Wang L et al. | — | 2024 | → |
| Selective targeting and modulation of plaque associated microglia via systemic hydroxyl dendrimer administration in an Alzheimer's disease mouse model. | Henningfield CM et al. | — | 2024 | → |
| SPI1-mediated macrophage polarization aggravates age-related macular degeneration. | Qi S et al. | — | 2024 | → |
| Spi1 regulates the microglial/macrophage inflammatory response via the PI3K/AKT/mTOR signaling pathway after intracerebral hemorrhage. | Zhang G et al. | — | 2024 | → |
| Summary statistics knockoffs inference with family-wise error rate control. | Yu CX et al. | — | 2024 | → |
| Supervised latent factor modeling isolates cell-type-specific transcriptomic modules that underlie Alzheimer's disease progression. | Hodgson L et al. | — | 2024 | → |
| Tracing ALS Degeneration: Insights from Spinal Cord and Cortex Transcriptomes. | Sneha NP et al. | — | 2024 | → |
| Unlocking the epigenetic symphony: histone acetylation's impact on neurobehavioral change in neurodegenerative disorders. | Basavarajappa BS et al. | — | 2024 | → |
| 3D genomics and its applications in precision medicine. | Chen M et al. | — | 2023 | → |
| A dynamical systems approach for multiscale synthesis of Alzheimer's pathogenesis. | Rollo J et al. | — | 2023 | → |
| Alzheimer's Disease Genetics: A Dampened Microglial Response? | Chatila ZK et al. | — | 2023 | → |
| Alzheimer's genes in microglia: a risk worth investigating. | Sudwarts A et al. | — | 2023 | → |
| A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation. | Ralvenius WT et al. | — | 2023 | → |
| Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier. | Kisler K et al. | — | 2023 | → |
| APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFβ-mediated checkpoints. | Yin Z et al. | — | 2023 | → |
| Bioinformatics pipeline to guide post-GWAS studies in Alzheimer's: A new catalogue of disease candidate short structural variants. | Lutz MW et al. | — | 2023 | → |
| Blood levels of MCP-1 modulate the genetic risks of Alzheimer's disease mediated by HLA-DRB1 and APOE for Alzheimer's disease. | Huang J et al. | — | 2023 | → |
| B lymphocytes ameliorate Alzheimer's disease-like neuropathology via interleukin-35. | Feng W et al. | — | 2023 | → |
| Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer's disease. | Ali T et al. | — | 2023 | → |
| Critical thinking of Alzheimer's transgenic mouse model: current research and future perspective. | Li X et al. | — | 2023 | → |
| Expression of <i>INPP5D</i> Isoforms in Human Brain: Impact of Alzheimer's Disease Neuropathology and Genetics. | Zajac DJ et al. | — | 2023 | → |
| Genetic associations with age at dementia onset in the PSEN1 E280A Colombian kindred. | Cochran JN et al. | — | 2023 | → |
| Genetic insights into immune mechanisms of Alzheimer's and Parkinson's disease. | Nott A et al. | — | 2023 | → |
| Genetic Polymorphisms in Oxidative Stress and Inflammatory Pathways as Potential Biomarkers in Alzheimer's Disease and Dementia. | Vogrinc D et al. | — | 2023 | → |
| Genome-wide association study in Alzheimer's disease: a bibliometric and visualization analysis. | Zhang J et al. | — | 2023 | → |
| Identification of novel genes for age-at-onset of Alzheimer's disease by combining quantitative and survival trait analyses. | Li YJ et al. | — | 2023 | → |
| <i>INPP5D</i>/SHIP1: Expression, Regulation and Roles in Alzheimer's Disease Pathophysiology. | Olufunmilayo EO et al. | — | 2023 | → |
| Insights into Alzheimer's disease from single-cell genomic approaches. | Murdock MH et al. | — | 2023 | → |
| Investigating Neuron Degeneration in Huntington's Disease Using RNA-Seq Based Transcriptome Study. | Sneha NP et al. | — | 2023 | → |
| Neurodegeneration cell per cell. | Balusu S et al. | — | 2023 | → |
| Neuroinflammation after ischemic stroke involves INPP5D expression mediated by the TMPO-AS1-PU.1 complex. | Luan W et al. | — | 2023 | → |
| Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders. | De Marchi F et al. | — | 2023 | → |
| The neuroimmune axis of Alzheimer's disease. | Jorfi M et al. | — | 2023 | → |
| Acquired immunity and Alzheimer's disease. | Feng W et al. | — | 2022 | → |
| Alzheimer's disease: Pathophysiology and dental pulp stem cells therapeutic prospects. | Xiong W et al. | — | 2022 | → |
| A Model of Discovery: The Role of Imaging Established and Emerging Non-mammalian Models in Neuroscience. | Haynes EM et al. | — | 2022 | → |
| APOE4 confers transcriptomic and functional alterations to primary mouse microglia. | Machlovi SI et al. | — | 2022 | → |
| APOE genetics influence murine gut microbiome. | Zajac DJ et al. | — | 2022 | → |
| Association of SPI1 Haplotypes with Altered SPI1 Gene Expression and Alzheimer's Disease Risk. | Cao H et al. | — | 2022 | → |
| BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia. | Sudwarts A et al. | — | 2022 | → |
| Bioinformatics pipeline to guide late-onset Alzheimer's disease (LOAD) post-GWAS studies: Prioritizing transcription regulatory variants within LOAD-associated regions. | Lutz MW et al. | — | 2022 | → |
| Cell type-specific histone acetylation profiling of Alzheimer's disease subjects and integration with genetics. | Ramamurthy E et al. | — | 2022 | → |
| Comprehensive Analysis of Immune Implications and Prognostic Value of SPI1 in Gastric Cancer. | Huang J et al. | — | 2022 | → |
| Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid β plaques. | Roy ER et al. | — | 2022 | → |
| Designing anisotropic porous bone scaffolds using a self-learning convolutional neural network model. | Lu Y et al. | — | 2022 | → |
| DNA methylation signatures of Alzheimer's disease neuropathology in the cortex are primarily driven by variation in non-neuronal cell-types. | Shireby G et al. | — | 2022 | → |
| Early-life stress elicits peripheral and brain immune activation differently in wild type and 5xFAD mice in a sex-specific manner. | Bachiller S et al. | — | 2022 | → |
| Evaluation of mild cognitive impairment genetic susceptibility risks in a Chinese population. | Zhang Y et al. | — | 2022 | → |
| Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1. | Restuadi R et al. | — | 2022 | → |
| Functional genomics of inflamm-aging and immunosenescence. | Lu RJ et al. | — | 2022 | → |
| Functional insight into LOAD-associated microglial response genes. | Jonas LA et al. | — | 2022 | → |
| Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies. | Lopes KP et al. | — | 2022 | → |
| Genetics of the human microglia regulome refines Alzheimer's disease risk loci. | Kosoy R et al. | — | 2022 | → |
| Genomics and Functional Genomics of Alzheimer's Disease. | Kamboh MI | — | 2022 | → |
| GhostKnockoff inference empowers identification of putative causal variants in genome-wide association studies. | He Z et al. | — | 2022 | → |
| Identification of HSC/MPP expansion units in fetal liver by single-cell spatiotemporal transcriptomics. | Gao S et al. | — | 2022 | → |
| <i>IGF1R</i> and <i>LOX</i> Modules Are Related to Antler Growth Rate Revealed by Integrated Analyses of Genomics and Transcriptomics. | Hu P et al. | — | 2022 | → |
| Infection and inflammation: New perspectives on Alzheimer's disease. | Whitson HE et al. | — | 2022 | → |
| Integrated bioinformatics-based identification of diagnostic markers in Alzheimer disease. | Chen D et al. | — | 2022 | → |
| Integrative Meta-Analysis of Huntington's Disease Transcriptome Landscape. | Sneha NP et al. | — | 2022 | → |
| Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease. | Horgusluoglu E et al. | — | 2022 | → |
| Landscape of immune infiltration in entorhinal cortex of patients with Alzheimer's disease. | Zhang H et al. | — | 2022 | → |
| Macrophages in health and disease. | Park MD et al. | — | 2022 | → |
| MethReg: estimating the regulatory potential of DNA methylation in gene transcription. | Silva TC et al. | — | 2022 | → |
| Microglia in Alzheimer's Disease: a Key Player in the Transition Between Homeostasis and Pathogenesis. | McFarland KN et al. | — | 2022 | → |
| Microglial efferocytosis: Diving into the Alzheimer's disease gene pool. | Romero-Molina C et al. | — | 2022 | → |
| Neuroimmune contributions to Alzheimer's disease: a focus on human data. | Haage V et al. | — | 2022 | → |
| Pathogenesis, therapeutic strategies and biomarker development based on "omics" analysis related to microglia in Alzheimer's disease. | Gao C et al. | — | 2022 | → |
| Single transcription factor efficiently leads human induced pluripotent stem cells to functional microglia. | Sonn I et al. | — | 2022 | → |
| The aging immune system in Alzheimer's and Parkinson's diseases. | Heavener KS et al. | — | 2022 | → |
| The impact of increasing levels of blood C-reactive protein on the inflammatory loci SPI1 and CD33 in Alzheimer's disease. | Huang J et al. | — | 2022 | → |
| Transcriptional and epigenetic regulation of microglia in maintenance of brain homeostasis and neurodegeneration. | Maurya SK et al. | — | 2022 | → |
| Upregulation of SPI1 during myocardial infarction aggravates cardiac tissue injury and disease progression through activation of the TLR4/NFκB axis. | Liu Z et al. | — | 2022 | → |
| A cortical immune network map identifies distinct microglial transcriptional programs associated with β-amyloid and Tau pathologies. | Patrick E et al. | — | 2021 | → |
| Advances in Genetic and Molecular Understanding of Alzheimer's Disease. | Ibanez L et al. | — | 2021 | → |
| A <i>multiple-causal-gene-cluster</i> model underlying GWAS signals of Alzheimer’s disease | Xu M et al. | — | 2021 | — |
| Alzheimer's-associated PU.1 expression levels regulate microglial inflammatory response. | Pimenova AA et al. | — | 2021 | → |
| A novel age-informed approach for genetic association analysis in Alzheimer's disease. | Le Guen Y et al. | — | 2021 | → |
| Apoptotic neurons and amyloid-beta clearance by phagocytosis in Alzheimer's disease: Pathological mechanisms and therapeutic outlooks. | Tajbakhsh A et al. | — | 2021 | → |
| Association of the CD2AP locus with cognitive functioning among middle-aged individuals with a family history of Alzheimer's disease. | Manzali SB et al. | — | 2021 | → |
| Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration. | Tan MS et al. | — | 2021 | → |
| Beyond association: successes and challenges in linking non-coding genetic variation to functional consequences that modulate Alzheimer's disease risk. | Novikova G et al. | — | 2021 | → |
| Causal Associations Between Modifiable Risk Factors and the Alzheimer's Phenome. | Andrews SJ et al. | — | 2021 | → |
| Cell-type-specific expression quantitative trait loci associated with Alzheimer disease in blood and brain tissue. | Patel D et al. | — | 2021 | → |
| Defining functional variants associated with Alzheimer's disease in the induced immune response. | Harwood JC et al. | — | 2021 | → |
| Genetically regulated expression in late-onset Alzheimer's disease implicates risk genes within known and novel loci. | Chen HH et al. | — | 2021 | → |
| Genetic dependency of Alzheimer's disease-associated genes across cells and tissue types. | Jaladanki SK et al. | — | 2021 | → |
| Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review. | Vogrinc D et al. | — | 2021 | → |
| Genome-Wide Landscape of North-Eastern European Populations: A View from Lithuania. | Urnikyte A et al. | — | 2021 | → |
| Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. | Yang C et al. | — | 2021 | → |
| Genomics of Alzheimer's disease implicates the innate and adaptive immune systems. | Li Y et al. | — | 2021 | → |
| GWAS-Top Polymorphisms Associated With Late-Onset Alzheimer Disease in Brazil: Pointing Out Possible New Culprits Among Non-Coding RNAs. | Kretzschmar GC et al. | — | 2021 | → |
| How understudied populations have contributed to our understanding of Alzheimer's disease genetics. | Dehghani N et al. | — | 2021 | → |
| How wide is the application of genetic big data in biomedicine. | Liu Y et al. | — | 2021 | → |
| Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: Potential role in Alzheimer's pathogenesis. | Salminen A et al. | — | 2021 | → |
| Integration of Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. | Novikova G et al. | — | 2021 | → |
| Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy. | Da Mesquita S et al. | — | 2021 | → |
| Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer's disease. | Jones RE et al. | — | 2021 | → |
| Multi-omics integration analysis identifies novel genes for alcoholism with potential overlap with neurodegenerative diseases. | Kapoor M et al. | — | 2021 | → |
| Multi-tissue neocortical transcriptome-wide association study implicates 8 genes across 6 genomic loci in Alzheimer's disease. | Gockley J et al. | — | 2021 | → |
| Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells. | Jing H et al. | — | 2021 | → |
| Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. | Farias FHG et al. | — | 2021 | → |
| Rare variants in the endocytic pathway are associated with Alzheimer's disease, its related phenotypes, and functional consequences. | Zhan L et al. | — | 2021 | → |
| Reassessment of Pioglitazone for Alzheimer's Disease. | Saunders AM et al. | — | 2021 | → |
| Role of Neuron and Glia in Alzheimer's Disease and Associated Vascular Dysfunction. | Bandyopadhyay S | — | 2021 | → |
| Set-based genetic association and interaction tests for survival outcomes based on weighted V statistics. | Li C et al. | — | 2021 | → |
| Sex-specific DNA methylation differences in Alzheimer's disease pathology. | Zhang L et al. | — | 2021 | → |
| Sleep/wake cycle alterations as a cause of neurodegenerative diseases: A Mendelian randomization study. | Cullell N et al. | — | 2021 | → |
| SUPERGNOVA: local genetic correlation analysis reveals heterogeneous etiologic sharing of complex traits. | Zhang Y et al. | — | 2021 | → |
| Systems modeling of metabolic dysregulation in neurodegenerative diseases. | Baloni P et al. | — | 2021 | → |
| The transcriptional landscape of Alzheimer's disease and its association with Wnt signaling pathway. | Martínez M et al. | — | 2021 | → |
| Ulmoidol, an unusual nortriterpenoid from Eucommia ulmoides Oliv. Leaves prevents neuroinflammation by targeting the PU.1 transcriptional signaling pathway. | Han R et al. | — | 2021 | → |
| Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress. | Zimmer TS et al. | — | 2021 | → |
| Using Mendelian randomization analysis to better understand the relationship between mental health and substance use: a systematic review. | Treur JL et al. | — | 2021 | → |
| VARAdb: a comprehensive variation annotation database for human. | Pan Q et al. | — | 2021 | → |
| A Genetics Perspective on the Role of the (Neuro)Immune System in Schizophrenia. | Birnbaum R et al. | — | 2020 | → |
| Alzheimer's Disorder: Epigenetic Connection and Associated Risk Factors. | Sharma VK et al. | — | 2020 | → |
| Alzheimer's Patient Microglia Exhibit Enhanced Aging and Unique Transcriptional Activation. | Srinivasan K et al. | — | 2020 | → |
| Antiviral Immune Response in Alzheimer's Disease: Connecting the Dots. | Roy ER et al. | — | 2020 | → |
| Association between alcohol consumption and Alzheimer's disease: A Mendelian randomization study. | Andrews SJ et al. | — | 2020 | → |
| Biological insights from multi-omic analysis of 31 genomic risk loci for adult hearing difficulty. | Kalra G et al. | — | 2020 | → |
| CELF2 regulates the species-specific alternative splicing of TREM2. | Yanaizu M et al. | — | 2020 | → |
| Cell Type-Specific Annotation and Fine Mapping of Variants Associated With Brain Disorders. | Doostparast Torshizi A et al. | — | 2020 | → |
| CRISPR-based functional genomics for neurological disease. | Kampmann M | — | 2020 | → |
| Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer's Disease. | Lewcock JW et al. | — | 2020 | → |
| Epigenetics: Recent Advances and Its Role in the Treatment of Alzheimer's Disease. | Xiao X et al. | — | 2020 | → |
| Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer's disease. | Zhang L et al. | — | 2020 | → |
| Functional genomics, genetic risk profiling and cell phenotypes in neurodegenerative disease. | Finkbeiner S | — | 2020 | → |
| Genetic and polygenic risk score analysis for Alzheimer's disease in the Chinese population. | Zhou X et al. | — | 2020 | → |
| Genetic architecture of Alzheimer's disease. | Neuner SM et al. | — | 2020 | → |
| Genetics of Alzheimer's disease: where we are, and where we are going. | Bellenguez C et al. | — | 2020 | → |
| Genetic variants and functional pathways associated with resilience to Alzheimer's disease. | Dumitrescu L et al. | — | 2020 | → |
| Human Brain Neuropharmacology: A Platform for Translational Neuroscience. | Dragunow M | — | 2020 | → |
| Human iPSC-derived microglia: A growing toolset to study the brain's innate immune cells. | Hasselmann J et al. | — | 2020 | → |
| Human Neural Stem Cell Systems to Explore Pathogen-Related Neurodevelopmental and Neurodegenerative Disorders. | Baggiani M et al. | — | 2020 | → |
| IL-33-PU.1 Transcriptome Reprogramming Drives Functional State Transition and Clearance Activity of Microglia in Alzheimer's Disease. | Lau SF et al. | — | 2020 | → |
| Immune and Inflammatory Pathways Implicated by Whole Blood Transcriptomic Analysis in a Diverse Ancestry Alzheimer's Disease Cohort. | Griswold AJ et al. | — | 2020 | → |
| Integrative genomics approach identifies conserved transcriptomic networks in Alzheimer's disease. | Morabito S et al. | — | 2020 | → |
| Microglia in Alzheimer's Disease. | Süß P et al. | — | 2020 | → |
| Microglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer's Disease Genetics. | Podleśny-Drabiniok A et al. | — | 2020 | → |
| Modeling Alzheimer's disease with iPSC-derived brain cells. | Penney J et al. | — | 2020 | → |
| Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. | Guo T et al. | — | 2020 | → |
| Murine Gut Microbiome Association With <i>APOE</i> Alleles. | Parikh IJ et al. | — | 2020 | → |
| Network pharmacology-based study on the mechanism of <i>Schisandra chinensis</i> for treating Alzheimer's disease. | Kun C et al. | — | 2020 | → |
| Neuroimmune Connections in Aging and Neurodegenerative Diseases. | Scheiblich H et al. | — | 2020 | → |
| Neurological Disorder Drug Discovery from Gene Expression with Tensor Decomposition. | Taguchi YH et al. | — | 2020 | → |
| Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology. | Sierksma A et al. | — | 2020 | → |
| Recent advances in genetic studies of alcohol use disorders. | Gupta I et al. | — | 2020 | → |
| Risk prediction of late-onset Alzheimer's disease implies an oligogenic architecture. | Zhang Q et al. | — | 2020 | → |
| ROS production and mitochondrial dysfunction driven by PU.1-regulated NOX4-p22<sup>phox</sup> activation in Aβ-induced retinal pigment epithelial cell injury. | Sun J et al. | — | 2020 | → |
| Shared genetic etiology underlying Alzheimer's disease and major depressive disorder. | Lutz MW et al. | — | 2020 | → |
| Shared genetic etiology underlying late-onset Alzheimer's disease and posttraumatic stress syndrome. | Lutz MW et al. | — | 2020 | → |
| Targeting Microglial Population Dynamics in Alzheimer's Disease: Are We Ready for a Potential Impact on Immune Function? | Martin-Estebane M et al. | — | 2020 | → |
| Tensor decomposition of stimulated monocyte and macrophage gene expression profiles identifies neurodegenerative disease-specific trans-eQTLs. | Ramdhani S et al. | — | 2020 | → |
| The good, the bad, and the opportunities of the complement system in neurodegenerative disease. | Schartz ND et al. | — | 2020 | → |
| The multiplex model of the genetics of Alzheimer's disease. | Sims R et al. | — | 2020 | → |
| Transcriptional Factors and Protein Biomarkers as Target Therapeutics in Traumatic Spinal Cord and Brain Injury. | Kumar S et al. | — | 2020 | → |
| Translating genetic risk of Alzheimer's disease into mechanistic insight and drug targets. | Sierksma A et al. | — | 2020 | → |
| Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions. | Liu W et al. | — | 2020 | → |
| A single-cell atlas of entorhinal cortex from individuals with Alzheimer's disease reveals cell-type-specific gene expression regulation. | Grubman A et al. | — | 2019 | → |
| A statistical framework for cross-tissue transcriptome-wide association analysis. | Hu Y et al. | — | 2019 | → |
| Bioinformatics strategy to advance the interpretation of Alzheimer's disease GWAS discoveries: The roads from association to causation. | Lutz MW et al. | — | 2019 | → |
| Blood-Brain Barrier: From Physiology to Disease and Back. | Sweeney MD et al. | — | 2019 | → |
| Brain cell type-specific enhancer-promoter interactome maps and disease<b>-</b>risk association. | Nott A et al. | — | 2019 | → |
| CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. | Pluvinage JV et al. | — | 2019 | → |
| Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions. | Elmaleh DR et al. | — | 2019 | → |
| Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. | Broce IJ et al. | — | 2019 | → |
| Endo-lysosomal dysregulations and late-onset Alzheimer's disease: impact of genetic risk factors. | Van Acker ZP et al. | — | 2019 | → |
| Epigenetic Modifications in Alzheimer's Neuropathology and Therapeutics. | Esposito M et al. | — | 2019 | → |
| Failures in Protein Clearance Partly Underlie Late Onset Neurodegenerative Diseases and Link Pathology to Genetic Risk. | Hardy J | — | 2019 | → |
| Genes, pathways and risk prediction in Alzheimer's disease. | Hardy J et al. | — | 2019 | → |
| Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. | Kunkle BW et al. | — | 2019 | → |
| Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms. | Takatori S et al. | — | 2019 | → |
| Genetic variability in response to amyloid beta deposition influences Alzheimer's disease risk. | Salih DA et al. | — | 2019 | → |
| Genome-Scale Transcriptional Regulatory Network Models of Psychiatric and Neurodegenerative Disorders. | Pearl JR et al. | — | 2019 | → |
| GWAS and Beyond: Using Omics Approaches to Interpret SNP Associations. | Chen HH et al. | — | 2019 | → |
| Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. | Golde TE | — | 2019 | → |
| Human iPSC application in Alzheimer's disease and Tau-related neurodegenerative diseases. | Tcw J | — | 2019 | → |
| Immune Signaling in Neurodegeneration. | Hammond TR et al. | — | 2019 | → |
| Inflammatory mechanisms in neurodegeneration. | Nichols MR et al. | — | 2019 | → |
| Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease. | Keaney J et al. | — | 2019 | → |
| Interleukin 9 alterations linked to alzheimer disease in african americans. | Wharton W et al. | — | 2019 | → |
| Investigating the energy crisis in Alzheimer disease using transcriptome study. | Dharshini SAP et al. | — | 2019 | → |
| Leveraging Human Induced Pluripotent Stem Cell-Based Models Provides Biological Context to Genome-wide Association Study Findings. | Brennand KJ | — | 2019 | → |
| Microglia in Brain Development, Homeostasis, and Neurodegeneration. | Bohlen CJ et al. | — | 2019 | → |
| [Neuroinflammation as motor of Alzheimer's disease]. | Castro-Gomez S et al. | — | 2019 | → |
| Phagocytosis in the Brain: Homeostasis and Disease. | Galloway DA et al. | — | 2019 | → |
| Promoter DNA hypermethylation - Implications for Alzheimer's disease. | Liu Y et al. | — | 2019 | → |
| Protective Variants in Alzheimer's Disease. | Andrews SJ et al. | — | 2019 | → |
| Rs2293871 regulates HTRA1 expression and affects cerebral small vessel stroke and Alzheimer's disease. | Liu G et al. | — | 2019 | → |
| Selene: a PyTorch-based deep learning library for sequence data. | Chen KM et al. | — | 2019 | → |
| Sex differences in the genetic predictors of Alzheimer's pathology. | Dumitrescu L et al. | — | 2019 | → |
| Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. | Spangenberg E et al. | — | 2019 | → |
| The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. | Deming Y et al. | — | 2019 | → |
| The latitude-dependent autoimmune disease risk genes ZMIZ1 and IRF8 regulate mononuclear phagocytic cell differentiation in response to vitamin D. | Parnell GP et al. | — | 2019 | → |
| The new genetic landscape of Alzheimer's disease: from amyloid cascade to genetically driven synaptic failure hypothesis? | Dourlen P et al. | — | 2019 | → |
| The Role of APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer's Disease. | Fernandez CG et al. | — | 2019 | → |
| The Transcriptional Landscape of Microglial Genes in Aging and Neurodegenerative Disease. | Bonham LW et al. | — | 2019 | → |
| Transcriptional and Epigenetic Regulation of Microglia in Health and Disease. | Yeh H et al. | — | 2019 | → |
| Translating Alzheimer's disease-associated polymorphisms into functional candidates: a survey of IGAP genes and SNPs. | Katsumata Y et al. | — | 2019 | → |
| Alzheimer's Disease: From Firing Instability to Homeostasis Network Collapse. | Frere S et al. | — | 2018 | → |
| A meta-analysis of public microarray data identifies biological regulatory networks in Parkinson's disease. | Su L et al. | — | 2018 | → |
| Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). | Zhong L et al. | — | 2018 | → |
| An APOE-independent cis-eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer's disease risk. | Rao S et al. | — | 2018 | → |
| A transcriptomic atlas of aged human microglia. | Olah M et al. | — | 2018 | → |
| Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. | Tapias V et al. | — | 2018 | → |
| Cell-specific histone modification maps in the human frontal lobe link schizophrenia risk to the neuronal epigenome. | Girdhar K et al. | — | 2018 | → |
| Circulating vitamin E levels and Alzheimer's disease: a Mendelian randomization study. | Liu G et al. | — | 2018 | → |
| Classifying Alzheimer's disease with brain imaging and genetic data using a neural network framework. | Ning K et al. | — | 2018 | → |
| Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer's Disease Models. | Lee CYD et al. | — | 2018 | → |
| Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. | Ising C et al. | — | 2018 | → |
| Genetic Modifiers in Neurodegeneration. | Jain N et al. | — | 2018 | → |
| Genetic risk for Alzheimer's disease is concentrated in specific macrophage and microglial transcriptional networks. | Tansey KE et al. | — | 2018 | → |
| Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. | Finucane HK et al. | — | 2018 | → |
| Identification of Alzheimer's Disease-Related Genes Based on Data Integration Method. | Hu Y et al. | — | 2018 | → |
| Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer's disease pathogenesis. | Zhou X et al. | — | 2018 | → |
| Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. | Shi Y et al. | — | 2018 | → |
| Loss of Trem2 in microglia leads to widespread disruption of cell coexpression networks in mouse brain. | Carbajosa G et al. | — | 2018 | → |
| Microglia from offspring of dams with allergic asthma exhibit epigenomic alterations in genes dysregulated in autism. | Vogel Ciernia A et al. | — | 2018 | → |
| Microglia in Alzheimer's disease. | Hansen DV et al. | — | 2018 | → |
| Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response. | Bachiller S et al. | — | 2018 | → |
| Microglial signatures and their role in health and disease. | Butovsky O et al. | — | 2018 | → |
| Network Medicine for Alzheimer's Disease and Traditional Chinese Medicine. | Jarrell JT et al. | — | 2018 | → |
| Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer's Disease: Are We There Yet? | Raikwar SP et al. | — | 2018 | → |
| New tricks for an ancient system: Physiological and pathological roles of complement in the CNS. | Tenner AJ et al. | — | 2018 | → |
| One for all and all for One: Improving replication of genetic studies through network diffusion. | Lancour D et al. | — | 2018 | → |
| PD-1 deficiency is not sufficient to induce myeloid mobilization to the brain or alter the inflammatory profile during chronic neurodegeneration. | Obst J et al. | — | 2018 | → |
| Polygenic analysis of inflammatory disease variants and effects on microglia in the aging brain. | Felsky D et al. | — | 2018 | → |
| PU.1 regulates Alzheimer's disease-associated genes in primary human microglia. | Rustenhoven J et al. | — | 2018 | → |
| Sex-specific genetic predictors of Alzheimer's disease biomarkers. | Deming Y et al. | — | 2018 | → |
| The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions. | Orme T et al. | — | 2018 | → |
| The GWAS Risk Genes for Depression May Be Actively Involved in Alzheimer's Disease. | Ni H et al. | — | 2018 | → |
| The identity and function of microglia in neurodegeneration. | Song WM et al. | — | 2018 | → |
| The potential importance of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of Alzheimer's disease. | Salminen A et al. | — | 2018 | → |
| The Therapeutic Potential of Metformin in Neurodegenerative Diseases. | Rotermund C et al. | — | 2018 | → |
| Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics. | Verheijen J et al. | — | 2018 | → |
| Untangling Genetic Risk for Alzheimer's Disease. | Pimenova AA et al. | — | 2018 | → |
| Using High-Throughput Animal or Cell-Based Models to Functionally Characterize GWAS Signals. | Dourlen P et al. | — | 2018 | → |
| Alzheimer's disease: A matter of blood-brain barrier dysfunction? | Montagne A et al. | — | 2017 | → |
| A Tale of Two Genes: Microglial Apoe and Trem2. | Pimenova AA et al. | — | 2017 | → |
| Genetic Pleiotropy between Nicotine Dependence and Respiratory Outcomes. | Zhang J et al. | — | 2017 | → |
| Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. | Efthymiou AG et al. | — | 2017 | → |
| Polygenic risk score analysis of pathologically confirmed Alzheimer disease. | Escott-Price V et al. | — | 2017 | → |
| Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss. | Hernandez MX et al. | — | 2017 | → |
| Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer's disease. | Lu Q et al. | — | 2017 | → |